ClariTrial | Search Clinical Trials

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

157 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

Phase 1Phase 2MTAP-deleted Solid Tumors

BAY 3713372

Bayer450 participants60 sites · United States, Australia, BelgiumCompletes Jun 2029

Compare CT.gov Full analysis →

Recruiting

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

Phase 2Pompe Disease

S-606001Placebo

Shionogi45 participants28 sites · United States, Belgium, DenmarkCompletes Aug 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Phase 1Phase 2Spasticity

CorabotasePlaceboDysport

Ipsen240 participants81 sites · United States, Austria, BulgariaCompletes Mar 2029

Compare CT.gov Full analysis →

Recruiting

Donepezil Versus Non-drug Treatment in Alzheimer's Disease.

Phase 3Alzheimer Disease, Early Onset

Donepezil

Assistance Publique - Hôpitaux de Paris240 participants1 site · FranceCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA

Phase 3Ischemic Stroke

Ticagrelor 90 MGCilostazol 100 MG

Kafrelsheikh University900 participants1 site · EgyptCompletes Sep 2024

Compare CT.gov Full analysis →

Recruiting

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Phase 1Phase 2Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed Cancer

LMP744Conventional Surgery or Biopsy

National Institute of Neurological Disorders and Stroke (NINDS)40 participants1 site · United StatesCompletes Dec 2030

Compare CT.gov Full analysis →

Recruiting

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Phase 1Phase 2Multiple SclerosisAlzheimer's Disease

[F-18]PBR06[C-11]PBR28

Brigham and Women's Hospital250 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

Phase 3Mesial Temporal Lobe Epilepsy

NRTX-1001NRTX-1001Sham Comparator

Neurona Therapeutics88 participants35 sites · United StatesCompletes Feb 2029

Compare CT.gov Full analysis →

Recruiting

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

Phase 3Alzheimer DiseaseDementiaPlaque, Amyloid

DonanemabPlacebo

Eli Lilly and Company550 participants59 sites · United States, Japan, Puerto RicoCompletes Sep 2029

Compare CT.gov Full analysis →

Recruiting

High Dose Steroids in Children With Stroke

Phase 3Paediatric Stroke

MethylprednisolonePrednisolone

Insel Gruppe AG, University Hospital Bern70 participants35 sites · Australia, Austria, DenmarkCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

Phase 1Phase 2Alzheimer's Disease

ABBV-1758Placebo for ABBV-1758ABBV-1758+1 more

AbbVie210 participants11 sites · United StatesCompletes Apr 2030

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Phase 2Early Alzheimer's Disease

MK-2214Placebo

Merck Sharp & Dohme LLC340 participants79 sites · United States, Argentina, AustraliaCompletes Apr 2029

Compare CT.gov Full analysis →

Recruiting

Molecular Imaging of NET Using [C-11]MRB-PET in MS

Phase 1Phase 2Multiple Sclerosis

[C-11]Methylreboxetine

Brigham and Women's Hospital19 participants1 site · United StatesCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Phase 3Migraine

Eptinezumab

H. Lundbeck A/S600 participants70 sites · United States, Argentina, CanadaCompletes Apr 2028

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

Phase 2Intracerebral Haemorrhage

Standard treatment+mirabegronStandard treatment

Tianjin Medical University General Hospital25 participants1 site · ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

1–15 of 157

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

157 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

Phase 1Phase 2MTAP-deleted Solid Tumors

BAY 3713372

Bayer450 participants60 sites · United States, Australia, BelgiumCompletes Jun 2029

Compare CT.gov Full analysis →

Recruiting

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

Phase 2Pompe Disease

S-606001Placebo

Shionogi45 participants28 sites · United States, Belgium, DenmarkCompletes Aug 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Phase 1Phase 2Spasticity

CorabotasePlaceboDysport

Ipsen240 participants81 sites · United States, Austria, BulgariaCompletes Mar 2029

Compare CT.gov Full analysis →

Recruiting

Donepezil Versus Non-drug Treatment in Alzheimer's Disease.

Phase 3Alzheimer Disease, Early Onset

Donepezil

Assistance Publique - Hôpitaux de Paris240 participants1 site · FranceCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA

Phase 3Ischemic Stroke

Ticagrelor 90 MGCilostazol 100 MG

Kafrelsheikh University900 participants1 site · EgyptCompletes Sep 2024

Compare CT.gov Full analysis →

Recruiting

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Phase 1Phase 2Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed Cancer

LMP744Conventional Surgery or Biopsy

National Institute of Neurological Disorders and Stroke (NINDS)40 participants1 site · United StatesCompletes Dec 2030

Compare CT.gov Full analysis →

Recruiting

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Phase 1Phase 2Multiple SclerosisAlzheimer's Disease

[F-18]PBR06[C-11]PBR28

Brigham and Women's Hospital250 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

Phase 3Mesial Temporal Lobe Epilepsy

NRTX-1001NRTX-1001Sham Comparator

Neurona Therapeutics88 participants35 sites · United StatesCompletes Feb 2029

Compare CT.gov Full analysis →

Recruiting

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

Phase 3Alzheimer DiseaseDementiaPlaque, Amyloid

DonanemabPlacebo

Eli Lilly and Company550 participants59 sites · United States, Japan, Puerto RicoCompletes Sep 2029

Compare CT.gov Full analysis →

Recruiting

High Dose Steroids in Children With Stroke

Phase 3Paediatric Stroke

MethylprednisolonePrednisolone

Insel Gruppe AG, University Hospital Bern70 participants35 sites · Australia, Austria, DenmarkCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

Phase 1Phase 2Alzheimer's Disease

ABBV-1758Placebo for ABBV-1758ABBV-1758+1 more

AbbVie210 participants11 sites · United StatesCompletes Apr 2030

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Phase 2Early Alzheimer's Disease

MK-2214Placebo

Merck Sharp & Dohme LLC340 participants79 sites · United States, Argentina, AustraliaCompletes Apr 2029

Compare CT.gov Full analysis →

Recruiting

Molecular Imaging of NET Using [C-11]MRB-PET in MS

Phase 1Phase 2Multiple Sclerosis

[C-11]Methylreboxetine

Brigham and Women's Hospital19 participants1 site · United StatesCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Phase 3Migraine

Eptinezumab

H. Lundbeck A/S600 participants70 sites · United States, Argentina, CanadaCompletes Apr 2028

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

Phase 2Intracerebral Haemorrhage

Standard treatment+mirabegronStandard treatment

Tianjin Medical University General Hospital25 participants1 site · ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

1–15 of 157